Clinical trials
for patients
Learn about available clinical trials
-
March 28, 2023PamplonaIn recruitment
ADCT-402-203 Clinical trial of loncastuximab tesirine and rituximab in ineligible/fragile, previously untreated patients with diffuse large B-cell lymphoma.
The objective of this study is to evaluate whether the investigational combination of loncastuximab tesirine (Lonca) with rituximab (R) is a safe and effective treatment for patients with untreated DLBCL. -
March 20, 2023PamplonaIn recruitment
20180257 Clinical trial of subcutaneous blinatumomab for the treatment of adults with relapsed or refractory B-precursor acute lymphoblastic leukemia.
The purpose of this study is to determine which doses of blinatumomab (the study drug) injected subcutaneously (just under the skin) are safe to give to patients. This study will also determine whether blinatumomab is safe and tolerable (has good or bad effects) at these doses and how blinatumomab acts inside the body when given in this way. -
March 20, 2023PamplonaIn recruitment
R668-BP-1902 Trial of dupilumab in adult patients with bullous pemphigoid.
The main objective of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. -
March 20, 2023MadridIn recruitment
17000139BLC3002 Clinical trial of TAR-200 with cetrelimab versus intravesical bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
The aim of this study is to compare the effects (both good and bad) of the investigational drug delivery system (TAR-200) in combination with cetrelimab with the effects of the comparative study drug BCG intravesical (drug that is placed directly into the bladder instead of being taken as a pill or injected into the veins) in patients with urothelial cancer. In addition to analyzing the effect of these treatments on bladder cancer, this study will also be used to find out how long the study drug... -
March 14, 2023PamplonaIn recruitment
EMN28/68284528MMY300 Clinical trial to compare daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autoleukel ciltacabtagene vs. daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplantation (ASCT)
The main objective of this study is to evaluate the efficacy of ciltacabtagene autoleucel (Ciltacel) compared to standard treatment with autologous stem cell transplantation (ASCT). -
March 14, 2023PamplonaIn recruitment
-
March 14, 2023PamplonaIn recruitment
GT-ORACLE Clinical trial to evaluate the safety and durability of GT005 in participants with geographic atrophy secondary to age-related macular degeneration treated in a previous Gyroscope-sponsored study
The aim of this study is to learn about the possible long-term effects of GT005 treatment and to determine whether GT005 is safe in the long term for patients with GA due to AMD. -
March 8, 2023PamplonaIn recruitment
20210143 Trial to evaluate the efficacy, safety and tolerability of rocatinlimab (AMG 451) in monotherapy in adult subjects with moderate to severe atopic dermatitis (AD).
The study is designed to confirm whether rocatinlimab is effective in treating patients with moderate to severe AD who have not responded to topical (applied externally to the skin) or other treatments and whether it is effective, well tolerated and causes any side effects. -
March 8, 2023MadridIn recruitment
C-800-25 Clinical trial of botensilimab (AGEN1181) in monotherapy and in combination with balstilimab (AGEN2034) or with investigator's choice of reference therapy (regorafenib or trifluridine and tipiracil) for the treatment of metastatic colorectal cancer.
The goal of this study is to learn whether a new type of immune-based treatment called botensilimab (also known as AGEN1181), alone or together with balstilimab (also known as AGEN2034), can help patients with RCC without IMS-A/dMMR. -
March 3, 2023PamplonaIn recruitment
RMC-6291-001 Clinical trial of RMC-6291 in monotherapy in subjects with advanced solid tumors with KRAS(G12C) mutation.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) in monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD) and recommended Phase 2 dose.